Last reviewed · How we verify
Standard of Care thromboprophylaxis
Standard of Care thromboprophylaxis prevents blood clot formation through established anticoagulant or antiplatelet mechanisms.
Standard of Care thromboprophylaxis prevents blood clot formation through established anticoagulant or antiplatelet mechanisms. Used for Venous thromboembolism prophylaxis in hospitalized patients, Surgical thromboprophylaxis, Atrial fibrillation stroke prevention.
At a glance
| Generic name | Standard of Care thromboprophylaxis |
|---|---|
| Sponsor | University of Iowa |
| Drug class | Anticoagulant/Antiplatelet (class varies by specific agent) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This refers to conventional thromboprophylaxis regimens (typically anticoagulants such as enoxaparin, unfractionated heparin, warfarin, or direct oral anticoagulants, or antiplatelet agents) used to prevent venous or arterial thromboembolism in at-risk patients. The specific mechanism depends on the agent used but generally involves inhibition of coagulation cascade factors or platelet aggregation.
Approved indications
- Venous thromboembolism prophylaxis in hospitalized patients
- Surgical thromboprophylaxis
- Atrial fibrillation stroke prevention
- Acute coronary syndrome
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
Key clinical trials
- Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement (NA)
- AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism: Study Protocol for the VTE-AI Randomized Trial. (NA)
- Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration. (NA)
- Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP) (PHASE3)
- Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention (PHASE4)
- Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum (NA)
- Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (PHASE3)
- Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |